Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 10, 2020

SELL
$15.7 - $20.84 $449,632 - $596,836
-28,639 Closed
0 $0
Q2 2020

Aug 05, 2020

BUY
$8.21 - $21.02 $235,126 - $601,991
28,639 New
28,639 $510,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $101M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Rmb Capital Management, LLC Portfolio

Follow Rmb Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rmb Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rmb Capital Management, LLC with notifications on news.